Remove Generic Drugs Remove Marketing Remove Pharmacy Remove Production
article thumbnail

Leading retail pharmacies in pharma

Pharmaceutical Technology

Increasing diagnosis of chronic diseases is expected to lead to fast growth in retail pharmacies. The rising incidence of long-standing diseases such as hypertension, diabetes, cardiovascular diseases, and cancer requires prolonged medication and, thus, drives the growth and need for retail pharmacies in the market.

Pharmacy 147
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Nothing epitomises market failures more than the cost of insulin,” Newsom said in a video posted on Twitter. California’s budget documents give few details about the tender process, but state that CalRx will spend $50 million to partner with a contract manufacturer to develop biosimilar insulin products in vial and pen form.

Insulin 328
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

XTalks

While the approval pathway for biosimilar products was established 12 years ago, there are still misconceptions about how biosimilars are approved, biosimilarity versus interchangeable status and which patients can be treated with biosimilars. Biosimilars are the “genericdrugs of the biopharma world. What is a Biosimilar?

article thumbnail

FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

The Pharma Data

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Biosimilars marketed in the U.S. for the treatment of diabetes.

Insulin 52
article thumbnail

Drug Channels News Roundup, February 2021: Accumulator Problems, Humana + ESI, White Bagging Battles, Buy-and-Bill Economics, and Pharmacy Hero Dave Marley

Drug Channels

In this issue: Payers confess: Patients lose from copay accumulators Humana joins the Express Scripts GPO Hospitals vs. PBMs over specialty pharmacy white bagging Let’s all follow the Buy-and-Bill Dollar! Plus, entrepreneurial pharmacy owner Dave Marley demonstrates the power of innovation. Marley Drug generated $1.7

article thumbnail

When FDA-Approved Generics Fail: Brand Wellbutrin XL Antidepressant is Cheaper from Canada

Pharmacy Checkers

Joe and Teresa Graedon, founders of The People’s Pharmacy , not only have an admirable track record of telling health consumers how it is, but also listening to those in their readership. In fact, many people reported that when they were switched to the Teva generic Wellbutrin XL, their depression returned. Compare Wellbutrin Prices.

article thumbnail

Does the Drug Shortage White Paper Fall Short?

FDA Law Blog

For generic drug manufacturing facilities specifically, the numbers are 63% and 87%. FDA previously analyzed 163 drugs that went into shortage in the 5-year period between 2013 and 2017; 63% (103) were sterile injectables and 67% (109) were drugs that have a generic version on the market.

Drugs 59